Long-term Progression-Free Survival: A pooled analysis of the MONALEESA trials revealed that 25% of patients with HR+/HER2- advanced breast cancer treated with Kisqali® (ribociclib) plus endocrine therapy remained progression-free for four or more years, with a median progression-free survival of 6.8 years.
Statistically Significant Overall Survival: Kisqali is the only CDK4/6 inhibitor to show statistically significant overall survival across all Phase III MONALEESA trials, reinforcing its effectiveness in treating metastatic breast cancer.
NATALEE Trial Findings: A five-year sub-analysis from the NATALEE trial demonstrated that Kisqali combined with a nonsteroidal aromatase inhibitor significantly improves distant disease-free survival compared to the aromatase inhibitor alone, applicable to a broad population of early breast cancer patients.
Biomarker Insights: The analysis identified clinical and genomic factors associated with long-term responses to Kisqali, emphasizing the role of precision medicine in optimizing treatment for patients with advanced breast cancer.
Wall Street analysts forecast NVS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVS is 127.75 USD with a low forecast of 112.00 USD and a high forecast of 143.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast NVS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVS is 127.75 USD with a low forecast of 112.00 USD and a high forecast of 143.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
4 Hold
1 Sell
Hold
Current: 145.000
Low
112.00
Averages
127.75
High
143.00
Current: 145.000
Low
112.00
Averages
127.75
High
143.00
Deutsche Bank
Buy
maintain
2026-01-16
Reason
Deutsche Bank
Price Target
AI Analysis
2026-01-16
maintain
Buy
Reason
Deutsche Bank raised the firm's price target on Novartis to CHF 125 from CHF 120 and keeps a Buy rating on the shares.
Barclays
Underweight -> Equal Weight
upgrade
2026-01-06
Reason
Barclays
Price Target
2026-01-06
upgrade
Underweight -> Equal Weight
Reason
Barclays upgraded Novartis to Equal Weight from Underweight.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NVS
Unlock Now
Barclays
Underweight -> Equal Weight
upgrade
$120
2026-01-06
Reason
Barclays
Price Target
$120
2026-01-06
upgrade
Underweight -> Equal Weight
Reason
As previously reported, Barclays upgraded Novartis to Equal Weight from Underweight with a CHF 120 price target as the firm transferred coverage of European large-cap pharma to a new analyst. The firm sees the company's "fairly rich" pipeline as mostly well reflected in valuation or with competition, says the analyst, who also cites a "weak" operational outlook for 2026.
Evercore ISI
Outperform
to
In Line
downgrade
$65 -> $72
2025-12-18
Reason
Evercore ISI
Price Target
$65 -> $72
2025-12-18
downgrade
Outperform
to
In Line
Reason
Evercore ISI downgraded Avidity Biosciences (RNA) to In Line from Outperform with a price target of $72, up from $65. Novartis (NVS) has agreed to acquire Avidity for $72 per share in cash and the acquisition is expected to close in the first half of 2026.
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
